Minimum investments vary for each fund. The structure of private equity funds historically follows a framework that includes classes of fund partners, management fees, investment horizons ...

The US company is paying $200 million upfront for rex-Asian rights to RemeGen's disitamab vedotin, with another $2.4 billion in possible future payments tied to future successes across multiple ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season Merck & Co., Inc ...